Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Aug;27(8):1500-1507.
doi: 10.1002/ejhf.3668. Epub 2025 Apr 21.

The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial

Sebastiaan Dhont  1   2 , Philippe B Bertrand  1   2 , Jonas Erzeel  1   2 , Sébastien Deferm  1   2 , Laurent Pison  1   2 , Pieter M Vandervoort  1   2 , Wilfried Mullens  1   2 , W H Wilson Tang  3   4 , Pieter Martens  1   2
Affiliations
Randomized Controlled Trial

The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial

Sebastiaan Dhont et al. Eur J Heart Fail. 2025 Aug.

Abstract

Aims: Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist. While catheter ablation is a key rhythm-control strategy in AF, its impact on MR severity remains uncertain. This study evaluates the effects of catheter ablation on AF recurrence, functional status, and MR progression in patients with AF and baseline MR.

Methods and results: This sub-analysis included 1423 patients (65% of the overall CABANA cohort) with available baseline echocardiography. Participants were randomized to catheter ablation or pharmacological therapy. The primary endpoint was the composite of all-cause mortality and cardiovascular hospitalization. Secondary endpoints included AF recurrence, changes in MR severity, and functional status. At baseline, 722 patients (52%) had MR, including 582 with mild and 140 with ≥moderate MR, with characteristics suggestive of an atrial functional mechanism. Catheter ablation significantly reduced AF recurrence compared to pharmacological therapy (odds ratio [OR] 0.56, 95% confidence interval [CI] 0.50-0.62, p < 0.001). The presence or absence of MR did not interact with randomization in terms of its neutral effect on all-cause mortality and cardiovascular hospitalization (p for interaction = 0.115). Baseline MR increased the risk of AF recurrence (OR 1.46, 95% CI 1.40-1.74, p < 0.001). However, the benefit of ablation on functional status was greater in patients with MR compared to those without (p for interaction < 0.001). Follow-up echocardiography (n = 248) showed a greater reduction in MR severity in the ablation group versus drug therapy (p for interaction = 0.040).

Conclusion: Catheter ablation was superior to pharmacological therapy in rhythm control and may reduce MR severity over time. These findings highlight ablation's potential structural and symptomatic benefits, pending specifically designed clinical trials.

Keywords: Atrial fibrillation; CABANA trial; Catheter ablation; Mitral regurgitation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage of persistent or long‐standing versus paroxysmal atrial fibrillation (AF) by mitral regurgitation (MR) severity.
Figure 2
Figure 2
Effect modification of atrial fibrillation (AF) ablation treatment on AF recurrence by mitral regurgitation (MR) status. CI, confidence interval; OR, odds ratio.
Figure 3
Figure 3
Distribution of mitral regurgitation (MR) severity at baseline and 1 year in ablation versus drug therapy. AF, atrial fibrillation.
See this image and copyright information in PMC

References

    1. Grayburn PA, Thomas JD. Basic principles of the echocardiographic evaluation of mitral regurgitation. JACC Cardiovasc Imaging 2021;14:843–853. 10.1016/j.jcmg.2020.06.049 - DOI - PubMed
    1. O'Gara PT, Mack MJ. Secondary mitral regurgitation. N Engl J Med 2020;383:1458–1467. 10.1056/NEJMcp1903331 - DOI - PubMed
    1. Kajimoto K, Sato N, Takano T. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction. Eur J Heart Fail 2016;18:1051–1059. 10.1002/ejhf.562 - DOI - PubMed
    1. Tamargo M, Obokata M, Reddy YNV, Pislaru SV, Lin G, Egbe AC, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:489–498. 10.1002/ejhf.1699 - DOI - PubMed
    1. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, et al. Atrial functional mitral regurgitation: JACC review topic of the week. J Am Coll Cardiol 2019;73:2465–2476. 10.1016/j.jacc.2019.02.061 - DOI - PubMed

Publication types

MeSH terms

Substances